Mark Pykett, VMD, PhD
Non-Executive Director, Member of the Remuneration Committee and Member of the Transaction Committee
Nationality: American
Date of initial appointment: December 11, 2020
Dr. Pykett has served as a Non-Executive Director since 2020.
Dr. Pykett is currently Chief Executive Officer of Orogen Therapeutics. Dr. Pykett currently also serves on the Board of Directors of the private companies InFlectis BioSciences, Exubrion Therapeutics and Myopax.
He was previously President and Chief Executive Officer of the Biotechnology company Myrtelle, Inc. Prior to that, Dr. Pykett was the Chief Scientific Officer of PTC Therapeutics.
Dr. Pykett was the President and Chief Executive Officer of Agilis Biotherapeutics from 2014 until its acquisition by PTC Therapeutics in 2018. Prior to Agilis, Dr. Pykett served as CEO of Navidea Biopharmaceuticals, President of Alseres Pharmaceuticals, President of Cygenics, and President and CEO of Cytomatrix.
Dr. Pykett holds a PhD in Molecular Biology from the University of Pennsylvania, a VMD from the University of Pennsylvania School of Veterinary Medicine, a B.A. in Biology from Amherst College and an MBA from Northeastern University.
ABOUT US | EXECUTIVE COMMITTEE | BOARD OF DIRECTORS | CORPORATE GOVERNANCE